While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".
A business making money today isn’t necessarily a winner, which is why we analyze companies across multiple dimensions at StockStory. That said, here are three profitable companies to steer clear of and a few better alternatives.
Genuine Parts (GPC)
Trailing 12-Month GAAP Operating Margin: 4%
Largely targeting the professional customer, Genuine Parts (NYSE: GPC) sells auto and industrial parts such as batteries, belts, bearings, and machine fluids.
Why Does GPC Give Us Pause?
- Scale is a double-edged sword because it limits the company’s growth potential compared to its smaller competitors, as reflected in its below-average annual revenue increases of 3.2% for the last three years
- Weak same-store sales trends over the past two years suggest there may be few opportunities in its core markets to open new locations
- Substandard operating margin profitability and its deterioration over the last year limit its responsiveness to unforeseen market trends
Genuine Parts’s stock price of $119.09 implies a valuation ratio of 15.1x forward P/E. If you’re considering GPC for your portfolio, see our FREE research report to learn more.
Haemonetics (HAE)
Trailing 12-Month GAAP Operating Margin: 19%
With roots dating back to 1971 and a mission to improve blood-related healthcare, Haemonetics (NYSE: HAE) provides specialized medical devices and software for blood collection, processing, and management across plasma centers, blood banks, and hospitals.
Why Is HAE Not Exciting?
- Absence of organic revenue growth over the past two years suggests it may have to lean into acquisitions to drive its expansion
- Modest revenue base of $1.32 billion gives it less fixed cost leverage and fewer distribution channels than larger companies
- ROIC of 6.6% reflects management’s challenges in identifying attractive investment opportunities
Haemonetics is trading at $62.60 per share, or 12x forward P/E. Dive into our free research report to see why there are better opportunities than HAE.
ASGN (ASGN)
Trailing 12-Month GAAP Operating Margin: 5.8%
Evolving from its roots in IT staffing to become a high-end technology consulting powerhouse, ASGN (NYSE: ASGN) provides specialized IT consulting services and staffing solutions to Fortune 1000 companies and U.S. federal government agencies.
Why Do We Pass on ASGN?
- Annual sales declines of 5.4% for the past two years show its products and services struggled to connect with the market during this cycle
- Estimated sales growth of 1.2% for the next 12 months is soft and implies weaker demand
- Earnings per share have contracted by 1.2% annually over the last five years, a headwind for returns as stock prices often echo long-term EPS performance
At $42.91 per share, ASGN trades at 8.6x forward P/E. Check out our free in-depth research report to learn more about why ASGN doesn’t pass our bar.
High-Quality Stocks for All Market Conditions
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
